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Abstract
In recent years, rabies virus-derived peptide (RDP) has shown promise as a specific neural 
cell targeting ligand, however stability of the peptide in human serum was unknown.  Herein, 
we report the molecular modelling and design of an optimised peptide sequence based on 
interactions of RDP with the 7 subunit of the nicotinic acetylcholine receptor (nAChR).  
The new sequence, named DAS, designed around a 5-mer sequence which demonstrated 
optimal nAChR binding in silico, showed greatly improved stability for up to 8 hours in 
human serum in comparison to RDP, which degraded within 2 hours at 37 °C.  In vitro 
analysis using SH-SY5Y neuroblastoma cells showed that DAS-conjugated nanoparticles 
containing the cytotoxic drug doxorubicin (DAS-Dox-NP) displayed significantly enhanced 
cytotoxicity compared with untargeted doxorubicin-loaded nanoparticles (Dox-NP).  DAS-
Dox-NP had no significant effect on non-neural cell types, confirming its neural-specific 
targeting properties. 
This is the first time that In this manuscript, we report the design and testing of an optimised 
peptide ligand, conjugated to a nanoparticulate delivery vehicle and specifically targeted to 
neural cells., has been reported. Future impact of an innovative targeting peptide ligand 
combining the ability to selectively identify the target and facilitate cellular internalisation 
could enable the successful treatment of many neural cell disorders.
Key words: peptide targeting, nanoparticle, drug delivery, neural cell, RDP
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Abbreviations
DAS – newly designed targeting peptide
DOX- doxorubicin
DOX-NP – unlabelled doxorubicin-loaded nanoparticles
α7 nAChR - nicotinic acetylcholine receptor alpha 7 subunit
NP- nanoparticles
PLGA- poly (lactic-co-glycolic) acid
RDP- rabies virus derived peptide
RDP-DOX-NP – RDP-labelled doxorubicin-loaded nanoparticles
DAS-DOX-NP – DAS-labelled doxorubicin-loaded nanoparticles
sc-DAS – scrambled version of the newly designed targeting peptide
sc-DAS-DOX-NP – scrambled DAS-labelled doxorubicin-loaded nanoparticles
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Introduction
Specific targeting of therapeutics is a growing area of research for a number of different 
disease states.  The benefits of this over conventional drug delivery are numerous, including 
improved bioavailability of the drug at the target organ, reduction of unwanted side effects 
and smaller dosages required for therapeutic effect.  Cell penetrating peptides (CPPs) can 
greatly enhance the intracellular uptake of conjugated cargo across biological membranes in a 
non-invasive, non-disruptive manner.  However, due to lack of tissue specificity, CPPs such 
as TAT (transactivating transcriptional activator) peptide, penetratin and polyarginine are not 
as efficient when aiming to deliver expensive or toxic drugs [1].  One group of diseases 
which are difficult to treat and may benefit from targeted delivery methods are neural cell 
disorders such as neuroblastoma [2-4] and neurosarcoma [5].
Neural cell-specific peptide targeting ligands have been explored in the past decade to deliver 
therapeutic agents in animal studies with success [6-10].  Many promising neural cell-specific 
targeting peptides take advantage of native receptors, transporters or enzymes to deliver 
therapeutic cargoes.  Derivatives from natural neurotoxic agents have been utilised due to 
their highly efficient transport abilities to nervous systems, such as tetanus toxin fragment C 
[11], neurotropic virus glycoproteins and fragments of snake, scorpion and bee venoms [10].  
Thus far, promising results with these ligands are still surrounded with concerns of immune 
reactions and true specificity for neural cells only.  Kumar et al. [6] first showed that a 
derivative of rabies virus glycoprotein (RVG), RVG-29, utilised nicotinic acetylcholine 
receptor (nAChR) transport to safely and non-invasively deliver siRNA to neuro-2a cells and 
mouse brain.  Following this success, derivatives of RVG have since been utilised to take 
advantage of this property for drug delivery to the CNS to treat a range of brain disorders 
[12-14].  
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RVG found in the rabies virus envelope, is responsible for viral entry into the nervous system 
[15]. Rabies virus-derived peptide (RDP) is a 39-amino acid derivative of RVG, which has 
shown early success as a neural cell-targeting ligand both in vitro and in vivo [16-19].  In 
previous work [20], we reported that RDP is dependent upon interaction with the nAChR and 
activity was inhibited by blocking the homomeric α7 subtype of this receptor, commonly 
found throughout the nervous systems.  An obstacle in the development of many peptide 
targeting ligands is the issue of serum instability due to proteolysis, hence breakdown of the 
peptide upon systemic administration.  This is particularly true for larger sequences of amino 
acids, which may be more susceptible to enzymatic degradation in vivo.  Fu et al. [16] 
reported that the approximate in vivo half-life of an RDP fusion protein in mice is only one 
hour.  The stability of RDP ligand alone in human serum has not yet been reported, however 
given its relatively large size it could be subject to stability issues in future studies.  
In this study, we report for the first time the molecular modelling, design and development of 
an optimised neural cell-targeting sequence, which we have termed DAS, based on 
interactions of RDP with the neural 7 nAChR subunit.  Furthermore, we report the 
enhanced stability of DAS in human serum compared to RDP and highlight its ability to 
specifically target neural cells with concomitant release of active nanoparticulate payloads. 
Materials and Methods 
Materials
Resomer® RG 502 H, Poly(D,L-lactide-co-glycolide)-PLGA, acid terminated (MW 7,000-
17,000), dichloromethane (DCM), poly(vinyl) alcohol (PVA) 87-89% hydrolysed- MW  
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85,000-124,000, MES hydrate, 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-
hydroxysuccinimide (NHS), trichloroacetic acid (TCA), human serum from male AB plasma 
(USA origin), α-cyano-4-hydroxycinnamic acid (CHCA) matrix, 3-[4,5-dimethylthiazol-2-
yl]-2,5 diphenyl tetrazolium bromide (MTT), hexamethonium and mecamylamine were all 
purchased from Sigma-Aldrich (UK).  RDP, DAS and scrambled DAS (sc-DAS) peptides 
were synthesised by GL Biochem (Shanghai) Ltd.  Nicotinic acetylcholine receptor-α7 
antibody was purchased from Santa Cruz Biotechnology, Inc. (USA).  Doxorubicin 
hydrochloride was obtained from VWR International (Pennsylvania, USA). Tissue culture 
reagents and media were purchased from Gibco®/ Life Technologies.  Human cancer cell 
lines, SH-SY5Y (human neuroblastoma) and HeLa (human cervical cancer), were cultured in 
RPMI 1640 medium as were the normal CHO (Chinese hamster ovary) cell line.  MDA-MB-
231 (human breast cancer) cells were cultured in DMEM medium.  Both RPMI 1640 and 
DMEM media were supplemented with 10% foetal bovine serum and 1% penicillin-
streptomycin (5,000U ml-1/5,000 µg ml-1).  All other chemicals were of analytical grade.
Design of novel targeting peptide
Step 1 Protein-ligand docking
Potential interactions between RDP and the α7 homomeric nAChR were explored, using α-
subunit residues 173-204 as a starting point in this study.  Original rabies virus glycoprotein 
(RVG) is reported to bind to these residues of the α1 nAChR subunit found at the 
neuromuscular junction (NMJ), hence facilitating the entry of the rabies virus into the 
nervous system [21, 22].  The coordinates of the neuronal nAChR α7 subunit, acetylcholine-
binding protein were obtained from the Protein Databank entry 3SQ6, chain A [23].  This 
was imported into CACHe Worksystem Pro (version 7.5.0.85; Fujitsu Ltd).  Hydrogen atoms 
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were added using the default settings in line with presumed protonation states for ionisable 
amino acid side-chains.  The positions of the added hydrogen atoms were optimised by 
locking the coordinates of all the non-hydrogen atoms and subjecting the system to a 
molecular mechanics (MM2) geometry optimisation. The 30-mer of RDP, 
KSVRTWNEIIPSKGCLRVGGRCHPHVNGGG, was divided into all possible contiguous 
ten amino acid fragments (residues 1-10; 2-11; 3-12 etc.) and each docked four times, using 
CACHe Worksystem Pro, into the prepared protein structure from 3SQ6 where the potential 
active site was defined as residues 173 – 204.  The amino acid side-chains in the defined 
active site were allowed to be flexible as were all rotatable bonds in the 10-mer proteins.  The 
genetic algorithm settings for the docking protocol included population size 50, maximum 
generations 3000, crossover rate 0.8, mutation rate 0.2 and convergence when the RMSD 
population fitness was less than 1. 
Step 2 Molecular dynamics simulations
The input files for molecular dynamics simulations of the docked protein-ligand complexes 
were prepared using the Antechamber module of the AMBER Tools package (Version 14) 
[24], implementing the ff14SB force field.  Disulphide bonds were enforced between the 
receptor residue pairs 125 & 138 and 186 & 187.  The system was neutralised by addition of 
sodium ions and then solvated within a truncated octahedron of TIP3P water molecules 
extending 8 Å from the surface of the protein.  Using the Amber 14 molecular dynamics 
package CUDA version [25-27], the system was energy-minimised for 2,000 cycles using a 
non-bonded cut-off of 12 Å and then heated under constant volume to 300 K over 25 ps 
under Langevin dynamics (time step = 1 fs).  The heating was continued at 300 K for a 
specified period under constant pressure also using Langevin dynamics (SHAKE on, time 
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step = 2 fs) using the Particle–Mesh–Ewald (PME) method to treat the long range 
electrostatic interactions with a 12 Å non-bonded cut-off. 
Step 3 Peptide design
Residues of interest from RDP (GCLRV) were identified from the work carried out in section 
2.2.1- 2.2.2 and were subsequently incorporated into the design of a new peptide.  A widely 
used flexible linking sequence -GGGGS- was subsequently added to the GCLRV sequence as 
a spacer in the design of a new peptide [28], to allow freedom of movement once conjugated 
to PLGA NP.  Finally, two glycine residues followed by an arginine tail consisting of 6 
alternating L- and D- arginine residues –GGRrRrRr- were also added to the sequence for 
enhanced stability and resistance to metabolic processes [29].  The new D-arginine-
containing 18-amino acid sequence, which we have termed DAS, was NH2-
GGGGSGCLRVGGRrRrRr-COOH.
Serum stability of RDP and DAS peptides
Peptide stability testing in human serum was carried out according to a previously detailed 
method [30].  Briefly, human serum was diluted to 25% with phosphate buffered saline (PBS) 
and subsequently centrifuged at 18809 g for 10 minutes to remove lipids, before incubating at 
37°C.  RDP and newly derived peptide, DAS, were prepared so that final serum peptide 
concentration was 10 µM prior to incubation at 37°C.  A 200 µL aliquot was removed from 
each serum-peptide mixture at various time points and reacted with 40 µL of 15% TCA for 
15 minutes at 4°C to remove larger serum proteins.  The collected samples were centrifuged 
at 18809 g to remove precipitated serum proteins for 10 minutes and supernatant collected for 
storage at -20°C.  Samples were analysed by MALDI-TOF mass spectrometry (PerSeptive 
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Biosystems Voyager-DE Biospectrometer, Herefordshire UK).  A 10 µL aliquot of serum 
sample was mixed with 10 µL of CHCA matrix (10 mg/mL fully dissolved), 1.5 µL of which 
was used for analysis.  The mass/charge ratio (m/z) was plotted against relative abundance.
Preparation of nanoparticles and conjugation of peptide to nanoparticles
Doxorubicin-loaded PLGA nanoparticles (Dox-NP) were prepared by a double emulsion 
technique and characterised according to methods previously described by this group [20].  
FITC-Dextran-loaded PLGA nanoparticles (FITC-NP) for confocal fluorescence imaging 
were also prepared and characterized using the method previously described in [20] using 4 
mg of FITC-Dextran per 100 mg of PLGA polymer.  Entrapment efficiency (EE) of FITC-
Dextran and doxorubicin in NP was determined using fluorescence spectroscopy (excitation 
485 nm, emission 520 nm) and UV-Vis absorbance (480 nm) respectively, on a FLUOstar 
Omega microwell plate reader (BMG Labtech, Germany). 
𝐸𝐸 =  𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑁𝑃 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑 𝑥 100%
Peptides were conjugated to nanoparticles according to methods previously described by this 
group [20].  
In vitro assays
Initial studies suggested that the presence of serum in the cell-based assay medium had 
minimal influence on the results of DAS-conjugated NP treatment (see Appendix 3). 
Therefore all assays were carried out in serum free medium to minimise possible interference 
associated with serum proteins in in vitro assays.
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In vitro cellular uptake study
Cellular uptake of FITC-NP preparations were evaluated in SH-SY5Y and HeLa cell lines 
using a Leica SP5 confocal microscope (x 63,000 magnification).  Cells were seeded onto 13 
mm glass coverslips at a concentration of 1x105 cells/mL (500 µL) and cultured in complete 
RPMI media at 37°C/5% CO2 overnight.  All existing media was aspirated and the cCells 
were treated with 1 mg/mL (500 µL) of either FITC-NP, RDP-FITC NP or DAS-FITC NP in 
serum free media (SFM) for 24 hours whilst incubating at 37°C/5% CO2.   Prior to imagining, 
all cells including controls were treated with 75 nM Lysotracker red in serum free media 
(SFM) for 30 minutes to visualise lysosomes in cells and track potential co-localisation with 
NP along the cellular internalisation pathway.   FITC fluorescence emission was collected 
between 510- 550 nm (excitation wavelength 490 nm).  Lysotracker emission was collected 
separately between 590-650 nm (excitation wavelength 580 nm). 
In vitro cytotoxicity study 
SH-SY5Y cells were plated out at a concentration of 1x105 cells/mL (96 well plate) in 
complete RPMI media and incubated at 37°C/5% CO2 for 16 hours.   A range of DAS Dox-
NP concentrations were initially tested to determine the most effective concentration to use 
for subsequent assays.  All existing media was aspirated and the cells were then treated with 
100 µL of serum free media (SFM) and either 60 µL of a 4 mg/mL NP suspension (final 
concentration 1.5 mg/mL) or an equivalent concentration of free peptide.  Control wells were 
treated with serum-free media only.  Cell viability was assessed after incubating for 24 hours 
(37°C/5% CO2), using an MTT assay.  To calculate cell viability, 25 µL of MTT (5 mg/ml) in 
PBS was added to each well on top of media and incubated at 37°C/5% CO2 for 2 hours.  
After this, all media was aspirated and cells solubilised with 70 µL of DMSO per well.  UV-
Vis absorbance was read at 570 nm and cell viability calculated.  To assess targeting 
specificity to neural cells, NP treatment was also added to non-neural cell lines CHO, HeLa 
and MDA-MB-231 according to the same protocol.  The cytotoxic effect of a scrambled 
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version of DAS (NH2-RVGGCSGGGGGLRrRrRr-COOH) conjugated to Dox-NP (scDAS-
Dox NP) was also assessed in SH-SY5Y cells.  
We demonstrated previously that RDP function could be blocked with nAChR inhibitors 
[20].  To determine whether nAChR antagonists would affect the activity of DAS, SH-SY5Y 
cells were first preincubated for 30 minutes with either 1 mM hexamethonium (competitive), 
1 mM mecamylamine (non-competitive) or anti- AChRα7 antibody (1:100 dilution), all in 
serum-free medium, prior to addition of Dox-NP or DAS-Dox NP, using the method 
described above. 
Statistical Analysis
All results reported were statistically analysed using an unpaired t-test. A p value of < 0.05 
was considered statistically significant.  
Results
Design of novel targeting peptide
A model of the receptor was built using the X-ray crystal structure coordinates from the 
Protein Databank, entry 3SQ6, chain A [23].  For the purposes of the docking experiments 
the active site was defined as residues 173 – 204. The 30-mer RDP peptide was divided into 
all possible contiguous ten amino acid fragments (residues 1-10; 2-11; 3-12 etc.) and docked 
into the receptor.  The 10-mer fragments were allowed full rotational flexibility as were the 
side-chains of the amino acids in the receptor active site.  Each fragment was docked four 
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times using a genetic algorithm protocol and the complexes were scored using potential of 
mean force (PMF: given in kcal/mol).  Since the genetic algorithm uses an initial random 
number seed, the best (lowest energy) result only is reported for each 10-mer fragment in 
Table 1.  [Table 1 near here].  The 10-mer fragment that gave the best binding enthalpy score 
(PMF energy) comprised residues 9-18 (IIPSKGCLRV).  The best-scoring complex from this 
fragment was subjected to molecular dynamics in explicit water for 100 ns.  After the first 50 
ns of simulation it was noticed that not all of the 10-mer was interacting with the receptor.  
Residues 9 – 12 (IIPS) in particular were positioned on average orthogonal to the receptor 
surface and engaged with water molecules.  A snapshot at 92 ns is shown in Figure 1 [Figure 
1 near here].  . 
Consequently, the initial receptor IIPSKGCLRV complex was cut down to a version 
containing residues 14-18 (GCLRV) and this complex was subjected to molecular dynamics 
in explicit water for 100 ns.  After a settling period of approximately 60 ns, the GCLRV 
fragment adopted a fairly stable conformation (RMSD plot shown in Appendix 1) on the 
surface of the receptor with each amino acid, except for the N-terminal glycine, making 
hydrogen bonding interactions.  Hydrophobic interactions with the receptor were also 
observed for the leucine and the valine residues in this fragment.  A two-dimensional view of 
the receptor-GCLRV interactions can be found in Appendix 2.  A new peptide (DAS) 
incorporating the GCLRV fragment from RDP was designed accordingly, consisting of 18 
amino acids (GGGGSGCLRVGGRrRrRr) as described earlier in this report.
Serum stability of RDP and DAS peptides
RDP and DAS were incubated in 25% human serum at 37°C and then analysed by MALDI-
TOF mass spectrometry to determine stability (Figure 2) [Figure 2 near here].  .  RDP with no 
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prior incubation (Figure 2B) gave rise to a peak consistent with its molecular weight of 4.6 
kDa.  Upon incubation in serum for 2 hours intact RDP was no longer detectable, however a 
new signal was detected between 2.7-3.2 kDa, most likely to be RDP breakdown fragments 
(Figure 2C).  A minimal trace of RDP remained in Figure 2D, suggesting RDP and its 
degradation products had continued to degrade over 8 hours.  Fully intact DAS expectedly 
gave rise to a peak at around 1.9 kDa indicated in Figure 2E, prior to incubation at 37°C.  
After 2 hours of incubation, approximately 60% of the signal remained, as shown in Figure 
2F.  After 8 hours in serum, a small amount of intact DAS remained as indicated (Figure 2G).  
Over the time course observed the new 18-mer peptide, DAS, was more resistant to 
degradation by serum proteases than RDP.
Characterisation of NP preparations
Particle size, zeta potential, drug content and peptide conjugation efficiency of the 
formulations are shown in Table 2.  PLGA NP were successfully loaded with either cytotoxic 
doxorubicin or FITC-Dextran with entrapment efficiencies of 64% and 77% respectively.  
[Table 2 near here].
In vitro cellular uptake
Visualisation of FITC-NP uptake by confocal fluorescence microscopy (Figure 3) 
demonstrates the ability of both RDP and DAS to preferentially target SH-SY5Y neural cells 
and promote cellular uptake compared to the untargeted FITC-NP [Figure 3 near here].  .  In 
contrast, detected fluorescence signal was low in Hela cells and no notable difference in 
cellular uptake was observed between all formulations, indicating that RDP and DAS do not 
function as targeting peptides in this non-neural cell line.  Furthermore, the signal detected by 
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Lysotracker red indicates that there may be co-localisation of lysosomes and internalised 
FITC-NP in SH-SY5Y cells.  
In vitro cytotoxicity study 
The IC50 of DAS Dox-NP was calculated to be 0.9 mg/mL (Figure 4) [Figure 4 near here]. 
Figure 5 4A shows the effect of DAS conjugation to Dox-NP in SH-SY5Y neural cells. 
Treatment with DAS-Dox NP caused a significant enhancement in SH-SY5Y cytotoxicity, as 
cell viability decreased to 60.0% (± 6.0% SD) compared with 82.7% (± 4.0% SD) when 
treated with untargeted Dox-NP.  Figure 5 4A also shows that neither free RDP nor free DAS 
peptides caused any significant decrease in cell viability.  In addition, when a scrambled 
version of the DAS peptide was conjugated to Dox NP (sc-DAS-Dox NP), there was no 
significant decrease in cell viability compared to untargeted Dox-NP treatment [Figure 5 4 
near here].  .
Figure 5 4B shows the effect of preincubating SH-SY5Y cells with the nAChR antagonists 
hexamethonium, mecamylamine and anti- AChRα7 antibody.  Pretreatment with all of the 
antagonists inhibits the cytotoxic effects of DAS-DOX-NP.  These results suggest that DAS 
is facilitating uptake of cytotoxic NP through mechanisms involving the nAChR.
The effects of DAS-DOX-NP on the non-neural cell lines HeLa, MDA-MB-231 and CHO are 
shown in Figure 6 5 [Figure 6 5 near here].  .  The cell viabilities for the normal, non-neural 
CHO cells and the cancer cell lines HeLa and MDA-MB-231 ranged narrowly from 62%-
75% between all NP-treated groups. In the neural cell line SHSY-5Y however, both RDP and 
DAS promote susceptibility of the cells to the cytotoxic effects of Dox-NP showing a 
statistically significant decrease in cell viability for both RDP-Dox NP (59.7% ± 4.7% SD) 
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and DAS-Dox NP (62.0% ± 9.8% SD) formulations compared to the untargeted Dox-NP 
(75.0% ± 7.1% SD).
Discussion
RDP is a peptide with a molecular weight of 4.6 kDa and, as such, its size may make it prone 
to proteolysis by serum proteases, which would severely limit its in vivo targeting ability and 
application.  Therefore, design of a smaller and more proteolytically resistant peptide, which 
retains the sequence essential for binding to the nAChR, could be very beneficial.  In earlier 
work, we reported that RDP requires the nAChR for function [20].  In this current work we 
modelled for interactions between RDP and the α7 nAChR subunit (which is specific to 
neural nAChR) [31] and uncovered a 5-amino acid section of the RDP sequence, -GCLRV-, 
which displays strong interactions with the α7 nAChR subunit and has potential for 
development as a new targeting sequence.  The addition of poly-arginine residues to a peptide 
has shown to promote water solubility and confer highly effective cell penetrating properties 
to a conjugated cargo whilst prolonging circulation time [29,32], therefore we included six 
arginine residues at the C terminal of the new peptide and included half of them as the 
protease-resistant D amino acid.  In doing this, the whole peptide should be less vulnerable to 
serum proteases and negatively charged plasma proteins, an effect which Liu et al. reported 
as similar to pegylation [32].  We also added the linker sequence -GGGGS- to the N terminal 
of the peptide, as described in the methods section, to allow free movement of the peptide 
once conjugated to the NP.
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The reported use of RDP as a neural cell-specific targeting ligand both in vitro and in vivo 
has been a promising step towards facilitating delivery of therapeutics to neural cells [16-19].  
However, there have been no reports on the stability of RDP in serum, with a previous 
stability study looking at RDP-conjugated nanoparticles concentrating on the stability of the 
payload and not the targeting peptide [33].
In this report, we have shown for the first time that RDP breaks down when incubated with 
human serum at 37°C within 2 hours (Figure 2C).  Although this may be long enough to 
demonstrate an effect in vivo, it would be desirable to optimise the peptide sequence to make 
it less prone to enzymatic degradation in serum.  If serum half-life could be extended then 
potential in vivo dosing would be lower and less frequent, which is preferable when utilising 
expensive or toxic therapeutic payloads.  Our findings show that the new DAS peptide 
displays a considerable improvement in stability characteristics compared to RDP, with mass 
spectrometry analysis detecting intact DAS peptide up to 8 hours after incubation in human 
serum at 37°C (Figure 2G).  D-amino acids, such as the D-arginine residues incorporated into 
DAS, have been used to improve the proteolytic resistance of peptides successfully within the 
area of drug delivery due to their ability to avoid quick metabolism [29,34].  There have also 
been many reports in the literature on the use of D-amino acid substitutions to promote serum 
stability of targeting peptides which aligns with the results reported here [35-39].  
In a previous publication, we demonstrated the use of RDP as a targeting ligand which 
enhanced the uptake of a conjugated nanoparticulate payload to induce cytotoxic effects in 
SH-SY5Y cells [20].  These findings are further supported by the confocal fluorescence 
images presented in Figure 3, which show RDP and DAS both facilitate NP uptake into 
neural cells specifically.  It has been suggested by Fu et al. [17], that the cellular uptake 
mechanism of RDP may involve energy-dependent internalisation pathways such as clathrin-
dependent endocytosis.  Indeed, observations of co-localisation between RDP and DAS 
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conjugates with lysosomes in our findings support this idea (Figure 3).  In addition, we have 
also demonstrated that, like RDP, DAS significantly enhances cytotoxicity of Dox-NP in SH-
SY5Y cells compared to untargeted DOX-NP and both free RDP and DAS peptides, which 
are non-toxic (Figure 5 4A).  When a scrambled version of DAS was conjugated to Dox NP 
(sc-DAS-Dox NP), there was no enhancement in cytotoxicity compared to untargeted Dox-
NP treatment (Figure 5 4A) demonstrating the necessity to retain the original –GCLRV- 
targeting sequence derived from RDP.
We also reported previously that nAChR antagonists prevented RDP action in SH-SY5Y 
cells [20] and the same inhibitors were employed to observe their effect on DAS peptide 
action.  Mecamylamine, hexamethonium and antibody against 7 subunit of homomeric 
neuronal nAChR were able to block the effects of DAS-DOX-NP confirming that DAS does 
indeed bind to neuronal nAChR in the same way as RDP (Figure 5 4B).    
The results displayed in Figure 6 5 confirm the specific action of DAS as a neural cell-
targeting ligand as it had no significant effect in three non-neural cell lines (HeLa, MDA-
MB-231 and CHO).   
In conclusion, the results described herein demonstrate that using molecular modelling and 
peptide design we have created a novel, bespoke neural cell nAChR targeting peptide, which 
we have termed DAS.  This peptide displays an enhancement in serum stability whilst 
retaining neural cell specificity, and aids efficient cellular uptake and release of nanoparticle 
payloads.  This targeted delivery system has potential for use in delivering therapeutics in a 
more specific manner to neural cells.
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Table 1. PMF docking scores for the 10-mer fragments ranked in order of score.
Fragment
PMF Docking 
Score 
(kcal/mol)
9_18 -815.10
17_26 -804.66
10_19 -791.05
12_21 -779.10
16_25 -767.22
11_20 -763.91
14_23 -754.99
8_17 -753.55
4_13 -752.98
21_30 -742.21
1_10 -728.43
18_27 -728.35
7_16 -723.68
13_22 -723.66
2_11 -721.83
6_15 -712.65
19_28 -703.93
20_29 -702.34
5_14 -693.11
3_12 -682.99
15_24 -639.01
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Table 2. PLGA nanoparticle characterisation parameters.
NP sample Sizea (d.nm)  ZPa (mV) DCb 
(µg/mg)
RDPc (µg/mg) DASd 
(µg/mg)
Dox-NP 242.7 ± 18.6 -14.6 ± 1.3 12.8 53.6 23.2
FITC-NP 286.5 ± 11.3 -10.3 ± 1.0 30.8 97.2 43.9
aSize and zeta potential (ZP) reported as average of three measurements ± standard 
deviation. bDC= drug content per 1 mg of NP based on entrapment efficiencies of 64% 
(Dox) and 77% (FITC); cRDP  content per 1 mg of NP based on conjugation efficiency of 
54% to Dox-NP and 73% to FITC-NP.  dDAS content per 1 mg of NP based on conjugation 
efficiency of 58% to Dox-NP and 88% to FITC-NP.  
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Appendix 1
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Appendix 2
Two-dimensional view of the receptor-ligand interactions for GCLRV at 74 ns in the molecular 
dynamics simulation
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Appendix 3
Cell viability of SH-SY5Y neuroblastoma cells following NP treatment in either serum-free medium (SFM) or 
with medium containing foetal bovine serum (complete).  Control groups were treated with either SFM or 
complete media only.  Cell toxicity was assessed by MTT assay following 24 hours of treatment at 37°C.  
*Statistically significant difference compared to Dox NP treatment (P value <0.05, n=6).
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Figure 1. Snapshot at 92 ns from the molecular dynamics simulation of fragment 
IIPSKGCLRV (stick form) with the nicotinic acetylcholine receptor (ribbon form). Residues 
IIPS are not in contact with the receptor surface.   
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Figure 2.  MALDI-TOF mass spectrometry analysis of peptide stability in 25% human serum 
at 37°C for various periods of time.  (A) Human serum with no peptide.  Profile detected for 
RDP (MW approx. 4.8kDa) in serum at time zero (B), 2 hours (C) and 8 hours (D) post 
incubation.  Peaks for intact peptide are indicated by a circle on the intensity/mass traces.  
DAS peaks (MW approx. 1.9kDa) for the same time points are shown (E)-(G) respectively.   
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 (B)                                            Lysotracker                                       FITC-Dextran 
 
 
Control 
 
 
 
 
 
 
FITC-NP 
 
 
 
 
 
 
 
RDP-FITC NP 
 
 
 
 
 
DAS-FITC NP  
 
 
Figure 3. Confocal images showing the effect of RDP and DAS labelling on the cellular 
uptake of FITC-NP (green) in (A) SH-SY5Y cells and (B) HeLa cells.   
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Figure 4.  Determination of IC50 of DAS-DOX-NP on SHSY-5Y cells.
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(A)
(B)
Figure 5 4. SH-SY5Y human neuroblastoma cell viability following treatment with (A) DAS-
conjugated doxorubicin-loaded NP (DAS-Dox NP) compared to free peptide and unlabelled 
doxorubicin NP (Dox-NP) and scrambled DAS NP.  Control samples were treated with 
serum-free media only.  (B) Effect of nAChR antagonists hexamethonium (Hex) and 
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mecamylamine (Mec) and antibody directed against alpha-7 subunit of homomeric neuronal 
nAChR (7-AB) on DAS ligand activity on SH-SY5Y neural cells.  * Statistically significant 
difference compared to Dox-NP (P value < 0.05). 
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Figure 6 5. Effect of peptide targeting ligands RDP and DAS on doxorubicin-loaded NP 
toxicity towards non-neural cell lines HeLa, CHO and MDA-MB-231 compared to SH-SY5Y 
neural cells. Control groups were treated with serum-free media only.  * Statistically 
significant difference compared to Dox-NP (P value < 0.05).
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